Cytokine responses to human immunodeficiency virus type 1 (HIV-1) induced by immunization with live recombinant canarypox virus vaccine expressing HIV-1 genes boosted by HIV-1SF-2 recombinant GP120

Vaccine

Volumn 19, Issue 13-14, 2001, Pages 1806-1819

  Gorse, Geoffrey J ^a   Patel, Gira B ^a   Mandava, Mahendra D ^a   Arbuckle, J Alan ^a   Doyle, Timothy M ^a   Belshe, Robert B ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cell mediated immunity; Cytokines; HIV 1; Vaccines

Indexed keywords

ALVAC HIV; CYTOKINE; GAG PROTEIN; GAMMA INTERFERON; GENE PRODUCT; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LIVE VACCINE; PROTEINASE; RECOMBINANT VACCINE; SF 2 RGP120; VIRUS ENVELOPE PROTEIN;

ARTICLE; CELL STIMULATION; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOUBLE BLIND PROCEDURE; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; MAJOR CLINICAL STUDY; MEMORY CELL; MONONUCLEAR CELL; MULTICENTER STUDY; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TH1 CELL; TH2 CELL; VIRUS GENE;

AIDS VACCINES; AVIPOXVIRUS; CYTOKINES; HIV CORE PROTEIN P24; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; IMMUNOLOGIC MEMORY; INTERFERON TYPE II; INTERLEUKINS; TH1 CELLS; TH2 CELLS; TIME FACTORS; VACCINATION; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 0035825572     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00378-9     Document Type: Article

References (72)

1. Cytokine patterns during the progression to AIDS
2. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses
3. The Th1-Th2 hypothesis of HIV infection: New insights
4. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
5. Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL), virus load, and CD4 T cell loss: Evidence supporting a protective role for CTL in vivo
6. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors
7. Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS
8. Different patterns of HIV-1-specific cytotoxic T-lymphocyte activity after primary infection
9. H2 cytokines on CD8+ cell response against human immunodeficiency virus: Implications for long-term survival
10. Demonstration of the Th1 to Th2 cytokine shift during the course of HIV-1 infection using cytoplasmic cytokine detection on single cell level by flow cytometry
11. CTL and neutralizing antibody responses with a combination HIV-1 vaccine regimen
12. Phase II evaluation of a live recombinant canarypox (ALVAC) vector HIV-1 vaccine with or without gp120 subunit HIV-1 vaccine
13. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with SF-2 rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers
14. The NIAID AIDS Vaccine Evaluation Group, Vaccine-induced cytotoxic T lymphocytes against human immunodeficiency virus type 1 using two complementary in vitro stimulation strategies
15. Novel features of the respiratory tract T-cell response to influenza virus infection: Lung T cells increase expression of γ-interferon mRNA in vivo and maintain high levels of mRNA expression for interleukin-5 (IL-5) and IL-10
16. Heterogeneity of helper/inducer T lymphocytes: II. Effects of interleukin 4- and interleukin 2-producing T cell clones on resting B lymphocytes
17. Interleukin 5 and interleukin 4 produced by Peyer's patch T cells selectively enhance immunoglobulin A expression
18. Interleukin-4
19. IL-4 (B cell-stimulatory factor 1) regulates multiple aspects of influenza virus-specific cell-mediated immunity
20. Regulation of cytolytic T-lymphocyte generation by B-cell stimulatory factor
21. Regulation of cytolytic cell populations from human peripheral blood by B cell stimulatory factor 1 (interleukin 4)
22. Interleukin-10
23. Review: Nomenclature and biologic significance of cytokines involved in inflammation and the host immune response
24. Interleukin-10
25. The NIAID AIDS Vaccine Clinical Trials Network. Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant gp160
26. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules
27. IIIB rgp120 subunit vaccine
28. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1
29. Human immunodeficiency virus (HIV-1) gp160-specific lymphocyte proliferative responses of mononuclear leukocytes from HIV-1 recombinant gp160 vaccine recipients
30. MN recombinant gp160 vaccine by dose and schedule of administration
31. MN recombinant glycoprotein 120 vaccine
32. SF-2 recombinant gp120, or both vaccines in seronegative adults
33. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: An alternative poxvirus vector system
34. Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species
35. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: Recombinant glycoprotein (rgp) 120, a randomized, double-blind trial
36. Isolation of mononuclear cells and granulocytes from human blood
37. Human interleukin-12 enhances interferon-γ-producing influenza-specific memory CD8+ cytotoxic T lymphocytes
38. The AIDS Vaccine Evaluation Group, Th1/Th2 cytokine responses following HIV-1 immunization in seronegative volunteers
39. Detection of intracellular antigen-specific cytokines in human T cell populations
40. Cytomegalovirus-specific IFN-γ and IL-4 are produced by antigen expanded human blood lymphocytes from seropositive volunteers
41. HIV-1 env DNA vaccine administered to rhesus monkeys elicits MHC class II-restricted CD4+ T helper cells that secrete IFN-γ and TNF-α
42. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime
43. Production of lymphokine mRNA by CD45R+ and CD45R- helper T cells from human peripheral blood and by human CD4+ T cell clones
44. Phenotypic and functional separation of memory and effector human CD8+ T cells
45. Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine
46. T4+ T helper cell function in vivo: Differential requirement for induction of antiviral cytotoxic T-cell and antibody responses
47. Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals
48. Cytokines and infectious diseases
49. Assessment of type 1 and type 2 cytokines in HIV type 1-infected individuals: Impact of highly active antiretroviral therapy
50. β-Chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques
51. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
52. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection
53. HIV versus cytotoxic T lymphocytes - The war being lost
54. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
55. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
56. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection
57. Characterization of a polyclonal cytolytic T lymphocyte response to human immunodeficiency virus in persons without clinical progression
58. Strong human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte activity in Sydney blood bank cohort patients infected with nef-defective HIV type 1
59. HIV-specific cytotoxic T-cells in HIV- exposed but uninfected Gambian women
60. HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant
61. Cytotoxic T lymphocyte responses in the peripheral blood of children born to human immunodeficiency virus-1-infected mothers
62. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein
63. Comparative clonal analysis of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines
64. Persisting human immunodeficiency virus type 1 gp160-specific human T lymphocyte responses including CD8+ cytotoxic activity after receipt of envelope vaccines
65. A phase I trial of vaccinia-env/gag/pol (TBC-3B) given by alternative routes, boosted by rgp120
66. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers
67. HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: Detection, characterization, and quantitation
68. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen
69. Human CD4+ cytolytic T lymphocyte responses to a human immunodeficiency virus type 1 gp160 subunit vaccine
70. An HIV-1 envelope protein vaccine elicits a functionally complex human CD4+ T cell response that includes cytolytic T lymphocytes
71. Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine
72. The NIAID AIDS Vaccine Clinical Trials Network, Recombinant gp160 vaccination schedule and MHC HLA types as factors influencing cellular responses to HIV-1 envelope glycoprotein